Neutropenia Clinical Trial
Official title:
A Prospective Observational Study of Plasma Voriconazole Concentration Measurement and Its Correlation With CYP2C19 Genotype in Korean Patients
Voriconazole (VCZ), the antifungal drug active against Candida and Aspergillus is a substrate of CYP2C19, whose proportion of poor metabolizers is about ~20% in Asian population. The AUC's of VCZ differs over 4 folds by CYP2C19 genotypes of homozygotic wild type, heterozygote, and homozygotic poor metabolizers. The Asian population enrolled in the metabolism of VCZ were mainly Japanese and Chinese, without Korean subjects. The proportion of poor metabolizers in Korean population is known to be around 12% (Pharmacogenetics. 1996 Dec;6(6):547-51). The importance of CYP2C19 genotypes on the pharmacokinetics (PK) of voriconazole is well established, Hence, it is desirable to individualize the dosage regimen of VCZ according to the genotypes of patients. Fungal infection in immunocompromised patients is a life threatening condition which needs critical care. Although the PK change by genotypes are well known, its clinical implication or need for different dosage regimen by genotypes is not established, yet.
The investigators are trying to set up voriconazole (VCZ) therapeutic drug monitoring (TDM) & establish relationship with efficacy and safety in Korea. The investigators also want to propose the optimal dosage regimen for VCZ over different genotypes of CYP2C19 in the immunocompromised patients in Korea. ;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02452034 -
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
|
Phase 1 | |
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT00020865 -
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
|
Phase 3 | |
| Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
| Completed |
NCT00020371 -
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
|
Phase 1 | |
| Terminated |
NCT00005787 -
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
| Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
| Not yet recruiting |
NCT02238873 -
Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
|
Phase 3 | |
| Completed |
NCT01058993 -
AMD 3100 for Treatment of Myelokathexis
|
Phase 1 | |
| Completed |
NCT00771810 -
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
|
Phase 2 | |
| Terminated |
NCT00529282 -
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
|
Phase 3 | |
| Completed |
NCT00771433 -
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
|
Phase 2 | |
| Completed |
NCT00770172 -
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
|
Phase 3 | |
| Active, not recruiting |
NCT00030758 -
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
|
Phase 4 | |
| Completed |
NCT00001790 -
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
|
Phase 1 | |
| Completed |
NCT00002693 -
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
|
Phase 1 | |
| Active, not recruiting |
NCT04154488 -
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
|
Phase 1/Phase 2 |